ArticleOncotarget2016

A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients.

Catherine Gallou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.